Navigation Links
First clinical trial of gene therapy for pain reported by U-M neurologists
Date:4/11/2011

Ann Arbor, Mich. In the first clinical trial of gene therapy for treatment of intractable pain, researchers from the University of Michigan Department of Neurology observed that the treatment appears to provide substantial pain relief.

In a study published online in the Annals of Neurology last week, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.

NP2 is a gene transfer vector that expresses the naturally-occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, M.D., Robert Brear Professor and chair of the Department of Neurology and his coworkers, had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation, or cancer.

In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain.

"The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink.

"In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80% reduction in pain over the course of 4 weeks following treatment."

Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the US subsidiary of Diamyd Medical.

The recombinant replication defective HSV approach represents a platform technology a nerve targeting drug delivery system (NTDDS) - that can be used to deliver and express any one of a number of genes in the nervous system. A related NTDDS vector, NG2 reduces pain-related behaviors in preclinical models of neuropathic pain from nerve injury and diabetes.

NTDDS gene transfer to the DRG to express neurotrophins locally prevents the progression of polyneuropathy in relevant preclinical models, suggesting that the NTDDS platform may be used to treat degenerative polyneuropathies as well.

"This is an example of translational research in which we have moved from laboratory bench studies through animal models into new treatment that we are testing patients. There was no placebo control in this phase 1 study, but the apparent dose-dependent pain relief was encouraging to us," Fink says.

A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.


'/>"/>

Contact: Mary F. Masson
mfmasson@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Medical Training School, Pima Medical Institute Offering First Bachelor's Degree Program
2. Retired Military Brass Support First Ladys Call to Reduce Child Obesity, Improve Nutrition
3. NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity
4. PolicyLink CEO Angela Glover Blackwell Released the Following Statement on First Lady Michelle Obamas Childhood Obesity Initiative
5. MSU launches first anti-counterfeiting research program
6. AMA Joins First Lady in Fight Against Childhood Obesity
7. National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Akron Institute of Herzing University Launches Its First Bachelors Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT
10. First Gene Variants Linked to Stuttering Discovered
11. FAB-HOMES™ Presents First Passive House Collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... ... Cornell, 52, was found dead on the night of Wednesday, May 17, 2017. It can ... the rock industry would take his own life, but the extremely talented and admired ... a role in the death of Chris Cornell . , Depression and Drug Use ...
(Date:5/21/2017)... ... 20, 2017 , ... GetLinked® software continues to ... financial systems. , Dozens of clubs using ABC Financial Services are now connected ... into their club’s accounting system , The latest implementation is Riverside Health ...
(Date:5/21/2017)... ... May 20, 2017 , ... Pot. Reefer. Grass. Mary Jane. ... it, and share its attributes like never before. More than a map, new social ... enthusiasts to stores, strains, products – and for the first time – each other. ...
(Date:5/21/2017)... ... ... Florida Pain Relief Group, a division of Physician Partners of America (PPOA), is ... Melbourne, on Monday, May 22. Initially the clinic will be supervised by Physician Partners ... 23 pain management clinics in Florida and the Dallas-Fort Worth, Texas metro area, and ...
(Date:5/21/2017)... PA (PRWEB) , ... May 21, 2017 , ... Following ... 2012, New York became the first state to require that hospitals follow a protocol ... controversy in the medical community as to whether such steps would have saved Rory ...
Breaking Medicine News(10 mins):
(Date:5/12/2017)...  The China and Canada joint tech ... water, energy and detergent, and features a powerful disinfection process. ... washing machine that washes and sanitizes women,s panties or babies, cloth ... ... does not require an external water inlet. ...
(Date:5/10/2017)... , May 10, 2017 Global Health ... Latin America , published its 2017 ranking ... ranking is based on extensive data analysis from GHI,s ... largest hospitals database for the region. The GHI database covers ... , offering more than 130 data points for each institution ...
(Date:5/10/2017)... 2017 CSSi, the global leader in patient ... industry, is proud to announce the launch of its ... features both enriched content and a customized layout that ... company,s already well-established position as the top global patient ... many months of hard work, we are delighted to ...
Breaking Medicine Technology: